Abstract

PurposeWe developed an accessible method for labeling small extracellular vesicles (sEVs) without disrupting endogenous ligands. Using labeled sEVs administered to conscious rats, we developed a multiple compartment pharmacokinetic model to identify potential differences in the disposition of sEVs from three different cell types.MethodsCrude sEVs were labeled with a non-homologous oligonucleotide and isolated from cell culture media using a commercial reagent. Jugular vein catheters were used to introduce EVs to conscious rats (n = 30) and to collect blood samples. Digital PCR was leveraged to allow for quantification over a wide dynamic range. Non-linear mixed effects analysis with first order conditional estimation – extended least squares (FOCE ELS) was used to estimate population-level parameters with associated intra-animal variability.Results86.5% ± 1.5% (mean ± S.E.) of EV particles were in the 45–195 nm size range and demonstrated protein and lipid markers of endosomal origin. Incorporated oligonucleotide was stable in blood and detectable over five half-lives. Data were best described by a three-compartment model with one elimination from the central compartment. We performed an observation-based simulated posterior predictive evaluation with prediction-corrected visual predictive check. Covariate and bootstrap analyses identified cell type having an influence on peripheral volumes (V2 and V3) and clearance (Cl3).ConclusionsOur method relies upon established laboratory techniques, can be tailored to a variety of biological questions regarding the pharmacokinetic disposition of extracellular vesicles, and will provide a complementary approach for the of study EV ligand-receptor interactions in the context of EV uptake and targeted therapeutics.

Highlights

  • Extracellular vesicles (EV) can be used to improve medical treatments if properly understood [1, 2]

  • Since EVs are continually secreted by virtually every eukaryotic cell, it is broadly accepted that the composition of any individual vesicle reflects the status of its originating cell at a particular moment in time

  • The validated XMIR-NT sequence was replaced with cel-miR-39-3p (XMc39) plasmid was transfected into 3 established rat-derived cell lines which produced EVs labeled with tracer miRNA

Read more

Summary

Introduction

Extracellular vesicles (EV) can be used to improve medical treatments if properly understood [1, 2]. They transport these contents to other nearby cells or to distant tissues via the blood circulation Targeted distribution of these vesicles is governed by surface markers, the composition of which is dependent on the originating cell [4,5,6]. Since EVs are continually secreted by virtually every eukaryotic cell, it is broadly accepted that the composition of any individual vesicle reflects the status of its originating cell at a particular moment in time. This dynamic heterogeneity in blood-circulating EVs makes the study of EV kinetics difficult [7, 8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call